{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:15:29Z","timestamp":1780632929398,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>High urinary activity in urinary bladder and ureters may hamper interpretation of prostate cancer and regional nodal metastases in prostate-specific membrane antigen (PSMA) PET\/CT. The goal of this study was to assess effects of furosemide and choice of tracer on urinary activity in the bladder and ureters, as well as on occurrence of peri-bladder artefacts in PET\/CT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Four cohorts with a total of 202 men staged with PSMA PET\/CT for prostate cancer received either <jats:sup>68<\/jats:sup>Ga-PSMA-11 as tracer, with (cohort G+) or without 10mg intravenous furosemide (G\u2212) concurrent with tracer, or <jats:sup>18<\/jats:sup>F-DCFPyL with (F+) or without furosemide (F\u2212). SUVmax of bladder and ureters, presence, type, and severity of peri-bladder artefacts were compared between cohorts. The influence of furosemide and choice of tracer was determined while taking differences in biodistribution time into account.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median SUVmax bladder was 43,5; 14,8; 61,7 and 22,8 in cohorts G\u2212, G+, F\u2212 and F+, respectively, resulting in significant overall (<jats:italic>p\u2009<\/jats:italic>&lt;\u20090.001) and between cohort differences (<jats:italic>p<\/jats:italic> adjusted &lt;\u20090.001 to 0.003) except between G\u2212 and F+. Median SUVmax ureter was 6.4; 4.5; 8.1 and 6.0 in cohorts G\u2212, G+, F\u2212 and F+, respectively, resulting in significant overall (<jats:italic>p\u2009<\/jats:italic>&lt;\u20090.001) and between cohort differences for G+ : F\u2212 and F\u2212 : F+ (<jats:italic>p\u2009<\/jats:italic>&lt;\u20090.001, respectively, 0.019). Significant effects of furosemide and choice of tracer on SUVmax bladder (<jats:italic>p\u2009<\/jats:italic>&lt;\u20090.001 resp. <jats:italic>p\u2009<\/jats:italic>=\u20090.001) and of furosemide on SUVmax ureter (<jats:italic>p\u2009<\/jats:italic>&lt;\u20090.001) were found, whereas differences in biodistribution time had not impacted these results significantly. Peri-bladder artefacts were present in 42\/202 (21%) patients and were significantly more frequent in the F\u2212 cohort, respectively, less frequent in the G+ cohort (<jats:italic>p\u2009<\/jats:italic>=\u20090.001 resp. <jats:italic>p\u2009<\/jats:italic>&lt;\u20090.001). Peri-bladder artefacts had a direct positive correlation with SUVmax bladder (<jats:italic>p\u2009<\/jats:italic>=\u20090.033).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Increased urinary activity and higher incidence of peri-bladder artefacts were found in <jats:sup>18<\/jats:sup>F-DCFPyL compared to <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT. Effective reduction of urinary activity may be reached through forced diuresis using 10mg intravenous furosemide, which is especially advantageous in <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-022-00913-y","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:45:56Z","timestamp":1659113156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET\/CT: a single-centre retrospective study"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2028-9713","authenticated-orcid":false,"given":"Maarten L.","family":"Donswijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurits","family":"Wondergem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"de Wit - van der Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha M.","family":"Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk G.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel P. M.","family":"Stokkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter V.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"913_CR1","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5:856\u201363.","journal-title":"JAMA Oncol."},{"key":"913_CR2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. The Lancet. 2020;395:1208\u201316.","journal-title":"The Lancet."},{"key":"913_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486\u201395.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"913_CR4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/1754-9485.12625","volume":"61","author":"N Fennessy","year":"2017","unstructured":"Fennessy N, Lee J, Shin J, et al. Frusemide aids diagnostic interpretation of (68) Ga-PSMA positron emission tomography\/CT in men with prostate cancer. J Med Imaging Radiat Oncol. 2017;61:739\u201344.","journal-title":"J Med Imaging Radiat Oncol."},{"key":"913_CR5","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1007\/s00330-016-4308-4","volume":"26","author":"T Derlin","year":"2016","unstructured":"Derlin T, Weiberg D, von Klot C, et al. (68)Ga-PSMA I&T PET\/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol. 2016;26:4345\u201353.","journal-title":"Eur Radiol."},{"key":"913_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/MNM.0000000000001007","volume":"40","author":"M Wondergem","year":"2019","unstructured":"Wondergem M, van der Zant FM, Rafimanesh-Sadr L, Knol RJJ. Effect of forced diuresis during 18F-DCFPyL PET\/CT in patients with prostate cancer: activity in ureters, kidneys and bladder and occurrence of halo artefacts around kidneys and bladder. Nucl Med Commun. 2019;40:652\u20136.","journal-title":"Nucl Med Commun."},{"key":"913_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00259-020-04846-3","volume":"48","author":"C Uprimny","year":"2020","unstructured":"Uprimny C, Bayerschmidt S, Kroiss AS, et al. Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [(68)Ga]Ga-PSMA-11-PET\/CT in the evaluation of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;48:123.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"913_CR8","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2967\/jnumed.120.257741","volume":"62","author":"I Alberts","year":"2021","unstructured":"Alberts I, Huenermund JN, Sachpekidis C, et al. Combination of forced diuresis with additional late imaging in (68)Ga-PSMA-11 PET\/CT\u2014effects on lesion visibility and radiotracer uptake. J Nucl Med. 2021;62:1257.","journal-title":"J Nucl Med."},{"key":"913_CR9","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.2967\/jnumed.120.261866","volume":"62","author":"C Uprimny","year":"2021","unstructured":"Uprimny C, Bayerschmidt S, Kroiss AS, et al. Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for (68)Ga-PSMA-11 PET\/CT. J Nucl Med. 2021;62:1550.","journal-title":"J Nucl Med."},{"key":"913_CR10","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, et al. Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"913_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","volume":"19","author":"G Ferreira","year":"2019","unstructured":"Ferreira G, Iravani A, Hofman MS, Hicks RJ. Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution. Cancer Imaging. 2019;19:23.","journal-title":"Cancer Imaging."},{"key":"913_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","volume":"18","author":"SP Rowe","year":"2016","unstructured":"Rowe SP, Macura KJ, Mena E, et al. PSMA-based [(18)F]DCFPyL PET\/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016;18:411\u20139.","journal-title":"Mol Imaging Biol."},{"key":"913_CR13","doi-asserted-by":"publisher","first-page":"e0246394","DOI":"10.1371\/journal.pone.0246394","volume":"16","author":"J Olde Heuvel","year":"2021","unstructured":"Olde Heuvel J, de Wit-van der Veen BJ, Sinaasappel M, Slump CH, Stokkel MPM. Early differences in dynamic uptake of 68Ga-PSMA-11 in primary prostate cancer: a test-retest study. PLoS One. 2021;16:e0246394.","journal-title":"PLoS One."},{"key":"913_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Haberkorn U, Schlemmer HP, et al. Comparison of PET\/CT and PET\/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887\u201397.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"913_CR15","doi-asserted-by":"publisher","first-page":"e0183329","DOI":"10.1371\/journal.pone.0183329","volume":"12","author":"T Heusser","year":"2017","unstructured":"Heusser T, Mann P, Rank CM, et al. Investigation of the halo-artifact in 68Ga-PSMA-11-PET\/MRI. PLoS ONE. 2017;12:e0183329.","journal-title":"PLoS ONE."},{"key":"913_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2214\/AJR.17.19356","volume":"211","author":"KA Wangerin","year":"2018","unstructured":"Wangerin KA, Baratto L, Khalighi MM, et al. Clinical evaluation of 68Ga-PSMA-11 and 68Ga-RM2 PET images reconstructed with an improved scatter correction algorithm. AJR Am J Roentgenol. 2018;211:655\u201360.","journal-title":"AJR Am J Roentgenol."}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-022-00913-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-022-00913-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-022-00913-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T14:23:14Z","timestamp":1659363794000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-022-00913-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1186\/s13550-022-00913-y","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"assertion":[{"value":"6 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This single-centre retrospective study was approved by the institutional review board of the Netherlands Cancer Institute, and the need for written informed consent was waived. Approval was registered under local number IRBd20-103. All methods were carried out in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}